We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




HDL Cholesterol Measurement Unaffected by Serum Amyloid A

By LabMedica International staff writers
Posted on 25 Feb 2019
Print article
Image: The JCA-BM8000 automatic analyzer series (Photo courtesy of JEOL).
Image: The JCA-BM8000 automatic analyzer series (Photo courtesy of JEOL).
High-density lipoprotein cholesterol (HDL) is known as the anti-atherogenic lipoprotein. Epidemiological studies have shown that low plasma concentrations of HDL are associated with an increased risk of cardiovascular events. HDL-cholesterol (HDL-C) is the only standardized parameter available to estimate the plasma HDL concentration.

Serum amyloid A (SAA) is a highly conserved, acute phase protein that is predominantly synthesized by the liver. During acute inflammation, SAA concentrations in the serum can increase to up to 1000-fold of the basal levels. Under these conditions, SAA displaces apolipoprotein A-I (apoA-I) in HDL and becomes the major apolipoprotein of circulating HDL.

Clinical biochemists from the Tokyo Medical and Dental University (Tokyo, Japan) and their colleagues obtained anonymized serum samples with various C-reactive protein (CRP) concentrations from 248 patients without clinically apparent liver disease. The SAA concentration of the serum samples were measured by latex agglutination turbidimetric immunoassay, and the serum samples were stratified into three groups, based on their SAA concentrations: low SAA (SAA ≤ 8 μg/mL, n = 94), middle SAA (8 < SAA ≤ 100 μg/mL, n = 37), and high SAA (SAA > 100 μg/mL, n = 117).

The team performed all assays on an automatic analyzer, JCA-BM8000 series. SAA and CRP were measured by the latex agglutination turbidimetric immunoassay using the LZ test ‘Eiken’ SAA and CRP-latexX2, respectively. HDL-C, low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC) and triglyceride (TG) levels were determined using commercial assays. The evaluation of HDL particle size was done with whole lipoproteins isolated by ultracentrifugation from randomly selected serum samples of patients with low or high SAA concentrations and was dialyzed against PBS and subjected to native-gel electrophoresis (native-PAGE) using 8% polyacrylamide gels.

The team reported that HDLs obtained from patients with low SAA concentrations were separated into their general particle sizes and classified as HDL2 and HDL3 by native-gel electrophoresis. On the other hand, HDLs obtained from patients with high SAA concentrations occasionally showed distributions different from the typical sizes of HDL2 and HDL3, such as extremely small or large particles. Nevertheless, HDL-C concentrations measured using the homogeneous assay was strongly correlated with those measured using the ultracentrifugation method, regardless of the SAA concentrations. However, the ratios of HDL-C concentrations obtained by the homogeneous assay to those obtained by the ultracentrifugation method for patients with high SAA concentrations were significantly lower than those of patients with low SAA concentrations.

The authors concluded that structural diversity, such as HDL particle size and SAA distribution, was observed in HDLs obtained from patients with inflammation; however, the HDL-C values measured by homogeneous assay were consistent with those obtained by ultracentrifugation method, regardless of SAA concentrations, an indicator of the presence or absence of inflammation. The study was published in the January 2019 issue of the journal Clinical Biochemistry.

Related Links:
Tokyo Medical and Dental University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.